Using a cell model system established by ectopic expression of a soluble TGFb type III receptor (sRIII) containing the whole extracellular domain of the type III receptor in human breast cancer MDA-MB-231 cells, we observed that the expression of sRIII antagonized TGFb activity and inhibited both anchorage-dependent and anchorage-independent cell growth. Further studies revealed that sRIII expression induced apoptosis both in vitro and in vivo. Treatment with TGFb neutralizing antibodies or a recombinant human sRIII also induced apoptosis in the MDA-MB-231 parental cells, suggesting that the increased apoptosis after sRIII expression was specifically due to antagonization of autocrine TGFb signaling. Western blotting showed that sRIII clones had a higher PTEN expression level than the control cells did. Treatment with TGFb 1 decreased PTEN and inhibited apoptosis in sRIII cells to a level similar to that in the control cells. sRIII clones also showed a lower level of phosphorylated-Akt than the control cells, consistent with the inhibitory activity of PTEN on Akt activation. Treatment with LY294002, a specific inhibitor of Akt activator, phosphatidylinositol 3-kinase, also induced apoptosis in a dose dependent manner in the control cells. Our results suggest that autocrine TGFb signaling is necessary for the growth and survival of MDA-MB-231 cells.
Introduction
Transforming growth factor beta (TGFb) is a secreted growth and differentiation factor regulating a variety of biological activities depending on the target cell and tissue type. Three isoforms of TGF-b named TGFb 1 , b 2 , and b 3 have been identified in mammals (Roberts and Sporn, 1991) . They all function by binding mainly to three different cell surface receptors called type I (RI), type II (RII) and type III (RIII) receptors. RIII (also called betaglycan) has high affinity for all three TGFb isoforms and can bind and present the ligands to RII to augment autocrine TGFb activity Lopez-Casillas et al., 1993; Wang et al., 1991) . RI and RII are serine/threonine kinase receptors (Bassing et al., 1994a; Franzen et al., 1993; Lin et al., 1992) . Binding of TGFb to RII recruits and transphos-phorylates RI (Bassing et al., 1994b; Wrana et al., 1994) . The activated RI phosphorylates intracellular Smad2 and Smad3, which then interact with Smad4 protein to form an oligomeric complex (Derynck et al., 1998; Massague´, 1998) . Once transported into nuclei, Smad2/Smad4 and Smad3/Smad4 complexes can act as transcriptional activator or repressor depending on cellular context (Massague and Chen, 2000; Piek et al., 1999) .
TGFb has been shown to be a potent growth inhibitor in a variety of cell types including epithelial cells . Because of this growth inhibitory activity, TGFb signaling components have been extensively examined with the notion that they should be tumor-suppressive. Indeed, TGFb RII was found mutated in colon and gastric carcinoma cells with microsatellite instability Myeroff et al., 1995) . A frameshift mutation of RI was identified in about one-third of ovarian cancers examined (Wang et al., 2000) . Mutations of Smad2 were found in colorectal carcinomas (Eppert et al., 1996) and mutations of Smad4/DPC4 were found in pancreatic carcinomas and juvenile polyposis Howe et al., 1998) . These mutations are believed to drive the progression of these distinct types of malignancy during late stages of carcinogenesis (Grady et al., 1998; Wilentz et al., 2000) . On the other hand, several studies showed that complete inactivation of TGFb signaling through mutations of RII or Smad proteins is restricted to certain types of cancer and is rare in other types of cancers with or without microsatellite instability. For example, breast, endometrial, pancreatic and lung carcinomas with microsatellite instability showed few or no RII mutation (Abe et al., 1996; Myeroff et al., 1995; Tomita et al., 1999) . Similarly, mutations of Smad proteins not including Smad2 and Smad4 were not found in 167 tumors of colon, breast, lung, and pancreas (Riggins et al., 1997) , and mutation of Smad4 is uncommon in breast and ovarian carcinomas . These studies suggest that autocrine TGFb signaling may be needed for the progression of certain types of cancer.
TGFb inhibits cell cycle progression mainly by inhibiting the expression of c-Myc and inducing the expression of p15Ink4b and p21Cip1 and consequently causing hyperphosphorylation of pRB (Massague, 2000) . Since tumor progression is often driven by inactivation of growth inhibitory genes such as pRB and overexpression of growth promoting genes such as c-myc, carcinoma cells are often resistant to TGFb's growth inhibitory activity while retaining a functional TGFb signaling pathway. For example, the human carcinoma DU145 cells are resistant to TGFb's growth inhibition due to mutational inactivation of pRB, but are sensitive to its regulation of gene expression (Murphy et al., 1991; Zentella et al., 1991) . Similarly, failure to inhibit c-Myc expression by TGFb was shown to cause the resistance to its growth inhibition in the human breast carcinoma MDA-MB-231 cells, which are responsive to TGFb with respect to the regulation of the expression of several other genes (Chen et al., 2001) . Currently, little is known about the role of autocrine TGFb signaling in these carcinoma cells that are not growth inhibited by TGFb. We hypothesized that carcinoma cells evade autocrine TGFb's growth inhibitory activity to gain growth advantages, however, they retain autocrine TGFb signaling for their survival and growth. To test this hypothesis, we examined the function of autocrine TGFb activity by expressing a truncated, soluble RIII (sRIII) in the human breast cancer MDA-MB-231 cell. Our results show that the expression of sRIII antagonized TGFb signaling, inhibited cell growth and induced apoptosis. Western blotting showed that sRIII-expressing cells had a higher PTEN expression level and a lower phosphorylated-Akt level than the control cells did. Furthermore, treatment with LY294002, a specific inhibitor of Akt activator, phosphatidylinositol 3-kinase, induced apoptosis in a dose dependent manner in the control cells. Our results, for the first time, suggest that autocrine TGFb is necessary for the growth and survival of human breast cancer MDA-MB-231 cells.
Results

Expression of sRIII attenuates TGFb signaling
The MDA-MB-231 cell line used in the study expresses detectable levels of active TGFb 1 and b 2 and is resistant to exogenous TGFb in growth inhibition assays . We have previously shown that ectopic expression of sRIII in the MDA-MB-231 cells sequestered active TGFb 1 and b 2 that were secreted by the sRIII-transfected cells. As a result, the medium conditioned by the sRIII-transfected cells showed significantly lower TGFb activity than that conditioned by the control cells when applied to a target cell line (Bandyopadhyay et al., 1999 ). In the current study, we have also investigated whether the secreted sRIII can attenuate TGFb induced signal transduction. Since Smad2 is known to be phosphorylated by RI upon TGFb treatment (Macias-Silva et al., 1996) , we compared the level of phosphorylated Smad2 between the control (Neo Pool) and sRIII clones. Figure 1a shows that twice as much Smad2 was phosphorylated in Neo Pool as in two sRIII clones after 30 min treatment with 2 ng/ml TGFb 1 . The basal level of phosphorylated Smad2 in the absence of TGFb was too low to be detected in all three cells. To determine whether the attenuation of TGFb signal by sRIII would also result in the attenuation of TGFb activity in gene expression, we transiently co-transfected a TGFb-responsive promoter-luciferase construct, pSBE4-Luc, and a b-galactosidase expression plasmid into Neo Pool and sRIII clones. The Neo Pool and sRIII clones were treated with 2 ng/ml TGFb 1 for 30 min. Cell lysates were collected and Western blot was performed as described in Materials and methods. Actin level is presented to indicate equal sample loading. The density of P-Smad2 bands was measured with Image-Pro Plus software (Media Cybernetics), normalized with that of the corresponding actin bands, and plotted in an arbitrary unit. (b) The effect of TGFb 1 on the activity of a TGFb-responsive promoter in Neo Pool and sRIII clones. MDA-MB-231 Neo Pool and sRIII clones were plated in 12-well plates and transiently transfected with pSBE4-Luc and b-gal constructs with FuGene 6. The transfected cells were treated with or without 5 ng/ml TGFb 1 . The activity of luciferase and b-gal were measured separately 48 h later. The luciferase activity was then normalized with b-gal activity in the same cell lysate. The results plotted represent the means+s.e.m. from triplicate transfections except for the value of sRIII c1.44+TGFb which represents the average from two transfections basal luciferase activity in Neo Pool was significantly (P50.05) higher than that in two sRIII clones suggesting that the expression of sRIII antagonized autocrine TGFb activity (Figure 1b) . Treatment of the transfected cells with exogenous TGFb 1 also caused a greater increase of the luciferase activity in Neo Pool than in sRIII clones (Figure 1b ). These as well as our published data (Bandyopadhyay et al., 1999) suggest that the expression of sRIII can antagonize exogenous and endogenous/autocrine TGFb activity in the MDA-MB-231 cells.
Autocrine TGFb activity supports the growth of MDA-MB-231 cells Autocrine TGFb has been shown to be a negative growth regulator in the cells that are growth inhibited by exogenous TGFb (Hafez et al., 1990; Wu et al., 1992) . However, the role of autocrine TGFb in regulating the growth of carcinoma cells that are not growth inhibited by exogenous TGFb is much less clear. Since sRIII expression can antagonize autocrine TGFb activity in the MDA-MB-231 cells, we compared the growth properties of Neo Pool and sRIII clones under various growth conditions. When the cells were plated at a high density on plastic so that the cultures become confluent in one week, the cell number of Neo Pool became significantly higher than those of the three sRIII clones during the exponential phase ( Figure 2a) . Similarly, treatment with a recombinant sRIII (R & D Systems) also inhibited the growth of MDA-MB-231 parental cells in a dose dependent manner (Figure 2b ). In a separate experiment, when we plated cells at a low density (400 cells/ well) in a 24-well plate and incubated for 2 weeks, the cell numbers of the sRIII clones were only about half of those of the Neo Pool ( Figure 3a ). The growth of the control cell in this type of assay was also significantly inhibited by the treatment with a TGFb 1 or a TGFb 2 neutralizing antibody (Ab) (Figure 3b ). The combination of the two neutralizing antibodies showed an additive effect. All three sRIII clones also grew much less than Neo Pool did when they were suspended in soft agarose (Figure 4) . A similar level of expression of sRIII in human colon carcinoma HCT116 cells with no autocrine TGFb activity due to the mutation of its type II receptor had no effect on the anchorage-independent growth in soft agarose (data not shown). These results suggest that the growth inhibition in the sRIIItransfected cells was not due to sRIII per se and that autocrine TGFb appears to support both anchoragedependent and anchorage-independent growth of the MDA-MB-231 cell.
Abrogation of autocrine TGFb signaling induces apoptosis
To determine how abrogation of autocrine TGFb signaling may inhibit the growth of MDA-MB-231 cells, we initially investigated the effect of sRIII expression on cell cycle progression and apoptosis.
Since sRIII clones showed the same pattern of cell cycle progression as Neo Pool (data not shown), we suspected that the reduced growth of sRIII clones might be due to increased cell death. Therefore, we used the Cell Death Detection ELISA kit from Roche Molecular Biochemicals, which measures the amount of histone-complexed DNA fragments, to compare apoptosis between Neo Pool and sRIII clones. Figure (Figure 6b ) also induced apoptosis as detected by Cell Death Detection ELISA suggesting that the increased apoptosis after sRIII expression was specifically due to its antagonization of autocrine TGFb signaling.
The sRIII transfectants were initially developed to determine whether sRIII could antagonize TGFb's tumor-promoting activity in vivo because TGFb had been shown to promote tumor growth and metastasis in various xenograft models and the mode of action was believed to be through its modulation of tumor stroma in favor of tumor cell growth and invasion (Reiss, 1999) . Expression of sRIII in the MDA-MB-231 cell significantly inhibited its tumorigenicity and metastasis in nude mice (Bandyopadhyay et al., 1999) . This tumor-suppressive activity of sRIII was mainly attributed to its ability to attenuate TGFb's activity in the stroma. With the finding that the abrogation of autocrine TGFb signaling by sRIII could induce apoptosis in MDA-MB-231 cells in vitro, we have also examined tissue sections of the tumors formed by Neo Pool and sRIII clones for apoptotic cells with a TUNEL assay. While the tumors formed by Neo Pool cells showed little staining, heavy staining indicating extensive cell apoptosis was observed in the tumors formed by sRIII clones (Figure 7 ). In contrast, the section from the Neo Pool-formed tumor showed more positive signals for the cell proliferation marker, proliferating cell nuclear antigen, than those from (a) Neo Pool and sRIII clones were seeded in a 24-well plate at 400 cells/well and incubated for 2 weeks. The relative cell numbers were determined with the MTT assay. The values are presented as means+s.e.m. of six optical density measurements from duplicate wells. (b) Neo Pool cells were plated at 400 cells/ well in a 24-well plate and treated with 20 mg/ml of a control antibody (Ab), a TGFb 1 neutralizing antibody, or a TGFb 2 neutralizing antibody respectively or in combination. The MTT assay was performed after 2 weeks of incubation. The values are presented as means+s.e.m. of six optical density measurements from duplicate wells. *indicates significant difference from the control value at P50.05 Figure 4 Anchorage-independent colony formation in soft agarose of MDA-MB-231 transfectants. Exponentially growing Neo Pool and sRIII clones (6000 cells) were resuspended in 1 ml of 0.4% low melting point agarose dissolved in the culture medium and plated on the top of a 1-ml underlayer of 0.8% agarose in each well of a 6-well plate. After 5 weeks of incubation, cell colonies were visualized by staining with 1 ml of p-iodonitrotetrozolium violet sRIII clone-formed tumors. Thus, sRIII expression can induce apoptosis in vitro as well as in vivo and the tumor suppressive activity of sRIII may be in part mediated by its attenuation of TGFb's survival signal in the tumor cells.
PTEN and AKT pathway mediates autocrine TGFb's survival signal
To elucidate potential pathways that may mediate autocrine TGFb's survival signal, we examined the expression of PTEN in the MDA-MB-231 transfectants. PTEN is a lipid phosphatase that antagonizes the activity of phosphatidylinositol 3-kinase by de-phosphorylating phosphatidylinositol 3,4,5-triphosphate (PtdIns-3,4,5-P3). Since PtdIns-3,4,5-P3 is necessary for the phosphorylation and activation of Akt, which supports cell survival, increased PTEN expression has been shown to inhibit Akt phosphorylation and induce apoptosis in various cell model systems including human breast carcinoma cells (Li et al., 1998; Simpson and Parsons, 2001) . PTEN transcription was shown to be inhibited by exogenous TGFb treatment in human keratinocytes (Li and Sun, 1997) . As shown in Figure 8a , Neo Pool expressed a low level of PTEN. Expression of the membrane-anchored wild-type RIII, which did not antagonize TGFb signaling (data not shown) Lopez-Casillas et al., 1994) , had no effect on PTEN expression. However, the expression of sRIII increased PTEN protein level in both clones. Treatment with TGFb 1 inhibited PTEN expression in sRIII cells in a dose dependent manner (Figure 8b ). In contrast, treatment with TGFb 1 did not decrease PTEN expression in Neo Pool suggesting that PTEN expression was inhibited by the autocrine TGFb. Furthermore, treatment with TGFb 1 had no effect on the apoptosis of Neo Pool, but inhibited apoptosis in sRIII cells (Figure 8c) .
Since PTEN is known to inhibit Akt phosphorylation by antagonizing the activity of phosphatidylinositol 3-kinase, we compared the level of phosphorylated Akt (P-Akt) between Neo Pool and sRIII clones with Western blotting. While the total Akt level was basically the same in Neo Pool and sRIII clones, its phosphorylation was noticeably inhibited in sRIII clones (Figure 9a ). To confirm that the inhibition of Akt activation could cause apoptosis in the MDA-MB-231 cell, we treated the control cell with LY294002, an inhibitor of phosphatidylinositol 3-kinase. Figure 9b shows that the treatment with LY294002 for 24 h induced apoptosis in a dosedependent manner. Thus, the data is consistent with the conclusion that abrogation of autocrine TGFb signaling appears to induce apoptosis in the MDA-MB-231 cell by the stimulation of PTEN expression and the inhibition of Akt activation.
Discussion
Mutational inactivation of TGFb receptors and Smad proteins in some cancers indicates that loss of TGFb signaling can cause tumor progression (Massague et al., 2000) . It is widely believed that the tumor suppressive activity of TGFb is mediated by its inhibition of cell cycle progression. Indeed, autocrine TGFb has been shown to inhibit cell proliferation in several human tumor model systems (Arteaga et al., 1990; Hafez et al., 1990; Wu et al., 1992) . Increased proliferation of hepatocytes was observed in TGFb 1 heterozygous null mice (Tang et al., 1998) . A large number of studies also showed that loss of or reduced The cultures of Neo Pool and sRIII cl.41 were treated with TGFb 1 at 0, 0.2, 1.0, 5.0 ng/ml for 24 h before being harvested for Western blotting with anti-PTEN and anti-actin antibodies. (c) Exponentially growing Neo Pool and sRIII cl.34 cells were plated in 6-well plates at 120 000 cells/well and treated without or with TGFb 1 at 1.0 ng/ml for 3 days. The cells were then harvested for Cell Death Detection ELISA as described in Materials and methods. Each column represents the average absorbance of two values from duplicate wells, which is depicted by the bar Figure 7 Staining of apoptotic or proliferating cells in tissue sections of tumors formed by Neo Pool and sRIII clones. Neo Pool and sRIII clones were inoculated subcutaneously in the inguinal mammary fat pad area of female athymic nude mice as previously described (Bandyopadhyay et al., 1999) . Tumors were harvested 8 weeks after inoculation. Tissue sections of a representative tumor formed by Neo Pool or sRIII clones were stained for apoptotic cells with a TUNEL assay or for proliferating cells with a PCNA staining kit. Images of stained sections from the center of each tumor were captured with a digital camera-fitted microscope under 2006 magnification. Positively stained cells are in brown color after TUNEL staining and in black brown color after PCNA staining TGFb growth inhibitory activity is common in many types of cancers including carcinomas, melanomas, lymphoid and myeloid malignancies (Reiss, 1999) . However, genetic studies have shown that mutational inactivation of TGFb signaling components is restricted to certain subsets of cancer. For example, mutations of TGFb RII and Smad4 are uncommon in breast cancer Tomita et al., 1999) . Thus, while various types of cancer cells are often resistant to TGFb's growth inhibitory activity, they retain an otherwise operational autocrine TGFb signaling pathway.
Currently, there are a limited number of studies on the role of autocrine TGFb signaling during tumor progression in carcinoma cells that are resistant to TGFb's growth inhibitory activity. Disruption of autocrine TGFb signaling with the expression of a dominant negative RII in mouse mammary and colon carcinoma cells significantly inhibited their invasive and metastatic potential (Oft et al., 1998) . This was attributed to the ability of the dominant negative RII in preventing autocrine TGFb-induced epithelial to mesenchymal transition since TGFb is known to induce epithelial to mesenchymal transition, a process believed to promote tumor cell migration and invasion (Bakin et al., 2000; Miettinen et al., 1994) . Expression of the dominant negative RII was also shown to inhibit bone metastasis of the MDA-MB-231 cells via the inhibition of TGFb-induced parathyroid hormonerelated protein production (Yin et al., 1999 ). In the current study, we investigated the effect of abrogation of autocrine TGFb signaling on the growth and survival of MDA-MB-231 cells. This cell line produces active TGFb 1 and TGFb 2 , and is resistant to TGFb's growth inhibitory activity (Chen et al., , 2001 ). The sRIII has been shown to act as a TGFb antagonist (Lopez-Casillas et al., 1994; Vilchis-Landeros et al., 2001) . Consequently, the expression of a sRIII in the MDA-MB-231 cells resulted in the sequestration of the active TGFbs and antagonization of their biological activity (Bandyopadhyay et al., 1999) . Using various growth assays, we found that the cultures of sRIIItransfected cells expanded significantly more slowly under both anchorage-dependent and anchorage-independent conditions than the control cell did. The growth inhibition was also observed when the control cell was treated with a recombinant sRIII or TGFb neutralizing antibodies. Significantly, sRIII expression did not retard cell cycle progression. Rather, it induced apoptosis in vitro and in vivo. Since the treatment with TGFb neutralizing antibodies also induced apoptosis, we conclude that autocrine TGFb signaling supports the survival of MDA-MB-231 cells.
While little has been reported on the role of autocrine TGFb in supporting carcinoma cell survival, exogenous TGFb was recently shown to protect serum starvation-induced apoptosis in epithelial cells through an Akt-dependent pathway (Shin et al., 2001) . Our unpublished studies also indicate that autocrine TGFb appears to support the growth and survival of human breast cancer MCF-7 cells. Other published studies have shown that antagonizing autocrine TGFb 1 activity with its neutralizing antibody can inhibit the growth and DNA synthesis in human colon and hepatocellular carcinoma cells (Hsu et al., 1994; Matsuzaki et al., 2000) . Since cell cycle analysis and apoptosis were not determined, it is not clear whether the inhibition of DNA synthesis by the TGFb 1 neutralizing antibody was due to a retardation of cell cycle progression or an enhanced apoptosis in those studies. Nevertheless, our results are consistent with the published studies suggesting a growth supportive role of autocrine TGFb signaling in some carcinoma cells.
Exogenous TGFb treatment has been shown to inhibit the expression of PTEN mRNA or protein in human keratinocytes or oncogenic Ras-transfected colon cancer cells respectively (Li and Sun, 1997; Yan et al., 2001 ). It has also been shown to induce Akt phosphorylation, which was found to be necessary for exogenous TGFb-induced epithelial to mesenchymal transition in a mouse mammary epithelial cell line (Bakin et al., 2000) . Since PTEN's tumor-suppressive activity is at least in part due to its pro-apoptotic activity by antagonizing phosphatidylinositol 3-kinasemediated Akt activation (Simpson and Parsons, 2001 ), we investigated whether autocrine TGFb supports cell survival by inhibiting PTEN expression in the MDA-MB-231 cell. The expression of sRIII was found to increase the level of PTEN protein and decrease the level of active Akt, phosphorylated Akt at Ser-473. Furthermore, inhibition of Akt activation by the treatment of a phosphatidylinositol 3-kinase inhibitor, LY294002, also induced apoptosis, whereas treatment with exogenous TGFb inhibited PTEN expression and apoptosis in the sRIII cells. Thus, autocrine TGFb appears to support cell survival by inhibiting PTEN expression in this model system. The fact that exogenous TGFb 1 did not inhibit PTEN expression in the control cell suggests that PTEN expression was maximally inhibited by the high levels of autocrine TGFb isoforms. Since increased expression of TGFb isoforms is known to be associated with the development and progression of various types of neoplasm including breast cancer Coombes et al., 1990; Daly et al., 1990; Gorsch et al., 1992; Walker and Gallacher, 1995) and TGFb has been shown to promote tumor progression in various models (Reiss, 1999) , we speculate that the high level of TGFb expression may stimulate tumor progression by inhibiting PTEN expression and promoting tumor cell survival in some cases.
Treatment with exogenous TGFb 1 has been shown to not only inhibit cell proliferation but also induce apoptosis in hepatocytes and some epithelial cells. However, significantly higher concentrations of TGFb 1 is generally required to induce apoptosis than to inhibit cell proliferation. For example, in primary cultures of fetal hepatocytes, the TGFb 1 concentration required to induce apoptosis is 2.5 ng/ml, which is five times that needed to inhibit cell growth (Sanchez et al., 1996) . In other systems such as murine myeloid cells, murine and human hepatocytes, rat prostate epithelial cells, and human prostate carcinoma cells, TGFb 1 concentrations at 5 to 10 ng/ml were required to induce apoptosis via different mechanisms (Chipuk et al., 2001; Landstrom et al., 2000; Perlman et al., 2001; Yamamura et al., 2000) . However, treatment of the MDA-MB-231 cell with TGFb 1 at 5 ng/ml for 3 days did not induce apoptosis in our hands (data not shown). Since the concentration of active TGFb isoforms in culture media conditioned by various cell types is normally in a picogram per milliliter range, the physiological and pathological significance of apoptosis induced by the abnormally high concentrations of TGFb remains to be elucidated. Although cancer cells often undergo spontaneous apoptosis, we are not aware of any report implicating autocrine TGFb as a direct effector causing the spontaneous apoptosis. On the other hand, our study suggests that autocrine TGFb may support the survival of carcinoma cells. Thus, while various mechanisms by which TGFb may promote tumor progression have been suggested or elucidated (Reiss, 1999) , our study furnishes yet another novel mechanism in support of therapeutic research targeting TGFb's tumor promoting activity in late stages of malignancy.
Materials and methods
Cell culture
Human breast carcinoma MDA-MB-231 cell was originally obtained from the American Type Culture Collection and adapted to McCoy's 5A medium containing 10% fetal bovine serum, pyruvate, vitamins, amino acids, and antibiotics (Mulder and Brattain, 1989) . Working cultures were maintained at 378C in a humidified incubator with 5% CO 2 .
Vector construction and transfection
A sRIII expression plasmid was constructed and transfected into a limiting dilution clone of the MDA-MB-231 cells as described previously (Bandyopadhyay et al., 1999) . Three sRIII-expressing clones and a pool of control vectortransfected clones (called Neo Pool) were used for the current study.
Transient transfection and luciferase assay
To compare TGFb sensitivity between Neo Pool and sRIII clones, we measured a TGFb-responsive promoter activity using a plasmid called pSBE4-Luc (Zawel et al., 1998) . The promoter activity is reported by luciferase. MDA-MB-231 Neo Pool and sRIII clones were plated at 150 000 cell/well in 12-well plates. The pSBE4-Luc plasmid (0.4 mg) and a bgalactosidase expression plasmid (0.1 mg) were transiently cotransfected into the cells using FuGene 6 (Roche Molecular Biochemicals) 24 h later. After 4 h of incubation, TGFb 1 was added at 5 ng/ml to the transfected cells. After an additional 44 h of incubation, cells were lysed and the activities of luciferase and b-galactosidase in the cell lysates were assayed as described previously . Luciferase activity was normalized to b-galactosidase activity before being plotted.
Anchorage-dependent growth assays
To study the effect of blockade of autocrine TGFb signaling on cell proliferation on plastic, two growth assays were performed. In the first assay, Neo Pool and sRIII clones were plated in 24-or 96-well culture plates at 8000 or 1600 cells/ well respectively. Relative cell number in each well was determined every 24 h after plating with MTT assay as described previously (Sun et al., 1994) . In the second assay, cells were plated in 24-well plates at 400 cells/well. After 2 weeks of incubation, relative cell number was determined with the MTT assay.
Soft agarose assay
To determine the effect of blockade of autocrine TGFb signaling on the ability of the cell to grow anchorageindependently in a semisolid medium, soft agarose assays were performed as described previously (Sun et al., 1994) . Briefly, 6610 3 cells were suspended in 1 ml of 0.4% low melting point agarose (Life Technologies) dissolved in the regular culture medium and plated on the top of a 1 ml underlayer of 0.8% agarose in the same medium in 6-well culture plates. After 5 weeks of incubation in the humidified incubator with 5% CO 2 at 378C, the cell colonies were visualized by staining with 1 ml of p-iodonitrotetrazolium violet staining (Sigma).
Cell death detection ELISA
Apoptosis-associated DNA fragmentation was quantified using the Cell Death Detection ELISA kit (Roche Molecular Biochemicals), which is based on the measurement of cytoplasmic histone-associated-DNA-fragments, mono-and oligo-nucleosomes. Exponentially growing cells were trypsinized, washed twice with cold PBS, and 200 ml lysis buffer was added per 3610 5 cells. After incubation at room temperature for 30 min, cell lysates were centrifuged at 200 g for 15 min to obtain cell extracts, which were used in the ELISA according to the manufacturer's instruction.
Annexin V-FITC staining
Annexin V-FITC (CALTAG Laboratories) and propidium iodide (PI) double staining was used to determine percentage of apoptotic cells. Exponentially growing cells were trypsinized, washed twice with cold PBS and resuspended in a binding buffer (10 mM HEPES/NaOH pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 ) at a concentration of 10 6 cells/ml. Annexin V-FITC (5 ml) and PI (10 ml of 50 mg/ml stock) were added to 100 ml of the suspended cells. The mixture was incubated at room temperature for 15 min in the dark. An additional 400 ml binding buffer was added before the cells were analysed with a flow cytometer. The number of cells stained positive with Annexin V-FITC and negative with PI was used for the calculation of percentage of apoptotic cells.
Western blot analysis
Exponentially growing cells were rinsed two times with ice-cold PBS and lysed in a cell lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40) containing protease inhibitor (Boehringer Mannheim) and phosphatase inhibitors, 1 mM NaVO 3 and 1 mM NaF. Equal amounts of total protein (50 -60 mg) were separated with SDS -PAGE and transferred to a PVDF membrane (Amersham Corp.). The membrane was blocked in TBST (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween-20) containing 5% non-fat powder milk and then incubated with a rabbit polyclonal anti-phospho-Smad2 (Ser-465/467) antibody (Upstate Biotechnology) or an anti-PTEN monoclonal antibody (Cell Signaling Technology) for 1 h at room temperature or overnight at 48C. After three washes with TBST, the membrane was incubated with HRP-linked antirabbit or anti-mouse antibody (Santa Cruz) for 1 h at room temperature and washed again. Bound complexes were visualized using chemiluminescence procedures (NEN Life Science Products) according to the manufacturer's instruction. The same membrane was subsequently blotted with an antiactin antibody (Sigma) to verify equal protein loading. To measure the level of activated Akt, an anti-phospho-Akt (Ser-473) antibody (Cell Signaling Technology) was used in Western blotting analyses, and an anti-total Akt antibody (Cell Signaling Technology) was used to verify equal protein loading.
Detection of apoptotic or proliferating cells in tumor sections
Tumors formed by MDA-MB-231 transfectants in nude mice from a previous study (Bandyopadhyay et al., 1999) were fixed in 10% buffered formalin (Fisher Scientific) and embedded in paraffin. Sections of 5 mm were cut from the embedded tumors and used for TUNEL staining. DNA fragmentation associated with apoptosis in tumor cells was detected in situ by the addition of digoxigenin-labeled nucleotides to label free 3'-end of DNA fragments using the ApopTag in situ apoptosis detection kit (Intergen) following the manufacturer's instruction. For the immunostaining of proliferating cell nuclear antigen (PCNA), a PCNA staining kit from Zymed was used according to the manufacturer's instruction. All stained sections were examined by light microscopy under 2006 magnification. Positively stained cells are in brown color after TUNEL staining and in black brown color after PCNA staining.
Statistical analysis
Student t-tests were used to determine a significant difference between control and experimental data (Zar, 1984) .
